Skip to main content

Table 3 Toxicities in Level-1 cohort

From: Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

Toxicity G1, % G2, % G3, % G4, %
Hematologic     
 Neutropenia 8 8 25 50
 Leukopenia 17 25 50 8
 Anemia 58 8 8 0
 Thrombocytopenia 25 8 0 0
Nonhematologic     
 AST increased 17 0 0 0
 ALT increased 17 0 8 0
 Anorexia 25 42 8 0
 Nausea 42 8 8 0
 Diarrhea 17 17 8 0
 Vomiting 8 0 8 0
 Stomatitis 25 17 0 0
 Constipation 58 8 0 0
 Fatigue 42 8 0 0
 Hypertension 8 8 0 0
 Peripheral neuropathy 8 8 0 0
 Weight loss 17 0 0 0
 Arthralgia 8 0 0 0
 Febrile neutropenia - - 8 0
 Intracranial hemorrhage 0 0 8 0
  1. ALT: alanine aminotransferase, AST: aspartate aminotransferase, G: Grade (according to the National Cancer Institute’s Common Toxicity Criteria for Adverse Events, version 4.0)